Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | HINT1 | P49773 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16777461 | 1.00 | HPGD (0.50) | HPGDADORA3ADORA2AHINT1NT5E | |
| SCHEMBL14842252 | 0.91 | ADORA2A (0.52) | HPGDADORA3ADORA2AHINT1NT5E | |
| SCHEMBL16777405 | 0.90 | HPGD (0.52) | HPGDADORA3ADORA2AHINT1NT5E | |
| SCHEMBL5203956 | 0.90 | PDE4D (0.53) | HPGDADORA3ADORA2AHINT1NT5E | |
| SCHEMBL313652 | 0.90 | PDE4D (0.53) | HPGDADORA3ADORA2AHINT1NT5E | |
| SCHEMBL4844756 | 0.89 | ADORA3 (0.51) | HPGDADORA3ADORA2AHINT1NT5E | |
| SCHEMBL546453 | 0.89 | ADORA3 (0.51) | HPGDADORA3ADORA2AHINT1NT5E | |
| SCHEMBL18636455 | 0.88 | HPGD (0.49) | HPGDADORA3ADORA2AHINT1NT5E | |
| SCHEMBL25380147 | 0.88 | ADORA2A (0.51) | HPGDADORA3ADORA2AHINT1NT5E | |
| SCHEMBL13929032 | 0.88 | ADORA2A (0.51) | HPGDADORA3ADORA2AHINT1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118234499-A | 2 '-Chloro-2' -fluoro-N for use in flavivirus therapy2-Amino-N6Methylaminopurine nucleotides | 阿堤亚制药公司 | 2024-06-21 | — | — | CN | disclosed |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | IDENIX PHARMACEUTICALS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | IDENIX PHARMACEUTICALS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170198005-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170198005-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
| WO-2015081133-A2 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015081297-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | RNMT, NUDT1, NTPCR | HPGD 2319/4885ADORA3 4/4885ADORA2A 14/4885 |
| US-20170198005-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | HAVCR2, SLC29A2, SLC28A2 | HPGD 4023/4885ADORA3 493/4885ADORA2A 223/4885 |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | RNMT, NUDT1, NTPCR | HPGD 2319/4885ADORA3 4/4885ADORA2A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.